AMPHAmphastar Pharmaceuticals, Inc.
Price
+2.5%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth fading, the market with it.
Charts
As reported to the SEC, without any scoring.
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $184M in Q2 2026 (quarter ended Jun 30, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 51% and net income of $30M (17% of revenue). For the full year FY2025, revenue was $720M (−1.7% year on year) and net income $98M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026.Earnings release · press release
- Jul 13, 2026On July 9, 2026, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), approved an increase to the authorized number of directors permitted to serve on the Board …Director or officer change · Form 8-K
- Jul 8, 2026On July 2, 2026, International Medication Systems, Limited (“IMS”), a subsidiary of the Company, received a warning letter (the "Warning Letter") from the FDA relating to IMS's drug manufacturing facility located in South El Monte, California.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #4 of 41 by RyuScore